Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 3/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 8/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | MLNR | O43193 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27014168 | 1.00 | SRD5A1 (0.41) | SRD5A1NAMPTIDO1HTR1AKDM5A | |
| SCHEMBL27014175 | 0.81 | SIGMAR1 (0.39) | SRD5A1IDO1HTR1A | |
| SCHEMBL27014164 | 0.78 | NAMPT (0.38) | SRD5A1NAMPTIDO1HTR1AKDM5A | |
| SCHEMBL25079094 | 0.72 | DRD2 (0.38) | SRD5A1NAMPTHTR1ADRD2HTR2A | |
| SCHEMBL11236466 | 0.71 | SRD5A1 (0.43) | SRD5A1IDO1DRD2HTR2AHTR2C | |
| SCHEMBL11236468 | 0.71 | SRD5A1 (0.43) | SRD5A1IDO1DRD2HTR2AHTR2C | |
| SCHEMBL11236464 | 0.71 | SRD5A1 (0.43) | SRD5A1IDO1DRD2HTR2AHTR2C | |
| SCHEMBL5395926 | 0.67 | SRD5A1 (0.45) | SRD5A1IDO1HTR2CSLC6A4HTR2B | |
| SCHEMBL29809159 | 0.67 | SRD5A1 (0.45) | SRD5A1IDO1HTR2CSLC6A4HTR2B | |
| SCHEMBL2242353 | 0.67 | SRD5A1 (0.45) | SRD5A1IDO1HTR2CSLC6A4HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018146-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018146-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ, INC. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018146-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | PINK1, NME4, AK2 | SRD5A1 4075/4885NAMPT 129/4885IDO1 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.